Guardant Health Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

GH$158.79+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (unaudited)

(in thousands, except per share data)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Revenue:
Precision oncology testing	$166,518	$125,244	$322,747	$238,637
Development services and other	10,717	11,906	22,979	27,227
Total revenue	177,235	137,150	345,726	265,864
Costs and operating expenses:
Cost of precision oncology testing	65,715	49,357	125,021	94,463
Cost of development services and other	6,706	4,491	12,696	12,458
Research and development expense	83,102	90,359	166,904	183,487
Sales and marketing expense	81,867	71,043	162,292	147,166
General and administrative expense	40,463	41,516	79,114	81,961
Total costs and operating expenses	277,853	256,766	546,027	519,535
Loss from operations	(100,618)	(119,616)	(200,301)	(253,671)
Interest income	13,913	6,727	28,781	9,787
Interest expense	(645)	(645)	(1,290)	(1,289)
Other income (expense), net	(15,145)	41,259	(44,265)	39,605
Loss before provision for income taxes	(102,495)	(72,275)	(217,075)	(205,568)
Provision for income taxes	133	496	538	736
Net loss	$(102,628)	$(72,771)	$(217,613)	$(206,304)
Net loss per share, basic and diluted	$(0.84)	$(0.67)	$(1.78)	$(1.95)
Weighted-average shares used in computing net loss per share, basic and diluted	122,447	108,808	122,080	105,752

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.